News & Press

  • Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021

    Regulatory press release

    Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...

  • Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

    Regulatory press release

    GOTHENBURG, Sweden, June 14, 2021 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 25, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market:...

  • Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

    Regulatory press release

    GOTHENBURG, Sweden, May 18, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market:...

  • Isofol completes recruitment of Japanese patients in the global phase III AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq...

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

    Regulatory press release

    GOTHENBURG, Sweden, April 28, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Non regulatory press release

    GOTHENBURG, Sweden, March 22, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

    Regulatory press release

    GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol reaches 440 patients in global Phase III AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    Non regulatory press release

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    Regulatory press release

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    Non regulatory press release

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...

  • Strengthened patent protection for arfolitixorin in Japan

    Non regulatory press release

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth...

  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    Non regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    Regulatory press release

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier...

  • Isofol's CEO Ulf Jungnelius has subscribed for all warrants

    Non regulatory press release

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...

  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    Regulatory press release

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First...

  • AGENT study update with regards to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s rights issue oversubscribed

    Regulatory press release

    GOTHENBURG, Sweden, June 3, 2020 - Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market:...

  • Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

    Non regulatory press release

    GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

    Regulatory press release

    GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market:...

  • Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Information in relation to COVID-19

    Non regulatory press release

    GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

    Regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market:...

  • The first patient included in Japan in Isofol's Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • Gene expression analysis method has been validated by a commercial laboratory

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • The Phase 1/2a study ISO-CC-005 is completed

    Non regulatory press release

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • The first patient included in Australia in Isofol's Phase 3 AGENT study

    Non regulatory press release

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...

  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)....

  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    Regulatory press release

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    Non regulatory press release

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol's board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    Regulatory press release

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    Non regulatory press release

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

    Non regulatory press release

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Non regulatory press release

    GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    Non regulatory press release

    GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Announces Election of Three New Board Members

    Non regulatory press release

    GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),...

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today...

  • Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

    Non regulatory press release

    GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    Non regulatory press release

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...

  • Isofol has participated in the Empowered Patient Podcast

    Non regulatory press release

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO...

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),...